AI analytics can be used as imaging biomarkers for predicting invasive upgrade of ductal carcinoma in situ

ConclusionThe AI-CAD score was an independent predictor of invasive upgrade for DCIS. Higher AI-CAD scores, especially in the highest quartile of ≥ 75%, can be used as an objective imaging biomarker to predict invasive upgrade in DCIS diagnosed with percutaneous biopsy.Critical relevance statementNoninvasive imaging features including the quantitative results of AI-CAD for mammography interpretation were independent predictors of invasive upgrade in lesions initially diagnosed as ductal carcinoma in situ via percutaneous biopsy and therefore may help decide the direction of surgery before treatment.Key points• Predicting ductal carcinoma in situ upgrade is important, yet there is a lack of conclusive non-invasive biomarkers.• AI-CAD scores—raw numbers, ≥ 50%, and ≥ 75%—predicted ductal carcinoma in situ upgrade independently.• Quantitative AI-CAD results may help predict ductal carcinoma in situ upgrade and guide patient management.Graphical Abstract
Source: Insights into Imaging - Category: Radiology Source Type: research